In May of 2013, FAST launched the most aggressive research program to date into finding a cure for Angelman Syndrome; The FAST Integrative Research Environment (FIRE).
FAST launched the FIRE initiative with 4 universities, 24 scientists and $650,000.00. Our goal was to grow the initiative in size and scope by investing $5 million dollars into the program over the next 4 years. To date, FAST has invested over $2.5 million into the FIRE initiative.
FIRE is a coordinated consortium of leading researchers working together to identify, characterise and implement new therapeutics for the treatment and ultimate cure of AS.
The consortium is designed to allow the production of new tools, development of novel, cutting-edge research and the sharing of information, discoveries, biological tools and valuable resources within the context of our mission. This integrative approach will allow for the development of therapeutics in the fastest, safest, most efficient and cost effective time frame possible.
Some of the brightest and most creative scientists have come together to accelerate the discovery of therapeutics for Angelman Syndrome and bring these findings from bench to bedside as rapidly as possible. We have now identified 4 potential drug therapy candidates, 2 potential gene therapy approaches and are developing 2 novel AS animal models.
The Foundation for Angelman Syndrome Therapeutics UK (or FAST) is an organisation dedicated to finding a cure for Angelman Syndrome and related disorders through funding research, education and advocacy. FAST UK intends to support UK based research that will function collaboratively with our United States counterparts, aimed at finding a specific treatment for Angelman Syndrome.
FAST UK is committed to facilitating the establishment of primary investigators in the UK, while maintaining a strong collaborative relationship with AS investigators and the FAST Integrative Research Environment (FIRE) in the United States.
FAST UK operate, and are bound by a constitution that outlines our objectives:
• To facilitate research on the prevention, detection and treatment of Angelman Syndrome;
• Provide the findings of this research and other information on the Disease to sufferers, carers, the public and the medical community;
• To engage in activities to raise public awareness of the Disease and particularly the characteristics, diagnosis and treatment of the Disease;
• To encourage the commencement of research into the Disease in the UK;
• To liaise with other national and international organisations associated with research and advocacy; and
• To participate in national and international studies and research projects into the Disease.